The Efficacy and Toxicity of Continuously L-asparaginase Administration on relapsed Canine Lymphoma
Date Issued
2010
Date
2010
Author(s)
Wu, Jun-Hong
Abstract
L-asparaginase (L-ASP) is an enzymatic chemotherapy agent derived from bacteria. There are two major advantages of using this drug which include unique pharmacologic mechanism (deprives tumor cells of that essential amino acid and inhibits protein synthesis) and very mild bone marrow suppression. According to previous studies, there are no significant benefits when L-ASP was used during the initiation of the treatment regime, however in recent years the use of L-ASP in relapsed lymphoma had been recommended by many oncologists. The purpose of this study is to exam the efficacy and toxicity associated with the addition of L-ASP into the treatment modality of relapsed canine multicentric lymphoma. The tumor response results were then compared with previous cases (control group) which have never receive any L-ASP treatment. Total of 40 dogs were included in the study. The overall response rate was 82.5% (52.5% CR, 30% PR), and median remission duration was 63 days (range, 17–778+ days). The side effects of L-ASP treatment were well- tolerated. Continuous L-ASP administration did not significantly prolong the overall survival time. In conclusion, the addition of L-ASP into the rescue protocol of relapsed canine lymphoma represents an effective re-induction method. This protocol may be a preferred rescue option before considering other treatment modality with higher toxicities.
Subjects
Dog
Lymphoma
Rescue protocol.
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-99-R96643006-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):83f1fea33c5f7bcbcd7ebb87112c9c69